Improving VEGF-targeted therapies through inhibition of COX-2/PGE(2) signaling

Antiangiogenic agents targeting the vascular endothelial growth factor A (VEGFA) pathway play an important role in current cancer treatment modalities but are limited by alternative angiogenesis mechanisms. Recent studies suggest that enhanced signaling through a COX-2/PGE(2) axis contributes to VEG...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Lihong, Croix, Brad St.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905212/
https://www.ncbi.nlm.nih.gov/pubmed/27308371
http://dx.doi.org/10.4161/23723548.2014.969154
Descripción
Sumario:Antiangiogenic agents targeting the vascular endothelial growth factor A (VEGFA) pathway play an important role in current cancer treatment modalities but are limited by alternative angiogenesis mechanisms. Recent studies suggest that enhanced signaling through a COX-2/PGE(2) axis contributes to VEGF-independent tumor angiogenesis. Thus, COX-2/PGE(2) inhibition may potentiate VEGF therapies.

Ejemplares similares